Pipeline & Data

A growing pipeline spanning multiple cancer types across differentiated constructs.

Pipeline Overview

Discovery Lead ID Candidate Preclinical IND-Enabling Phase 1 Phase 2 Phase 3
ISB-20 Lead Candidate
Breast · Prostate
Preclinical
ISB-21 Quad-Target Modality
Breast (TNBC) · Prostate · NSCLC
Preclinical
ISB-22 Nanobody Conjugate
Colorectal · NSCLC · Head & Neck
Discovery
ISB-14 Core Platform
Core
Preclinical
Current Stage
Completed
Upcoming
TBDS Platform Portfolio Four differentiated constructs addressing distinct tumor targets and indications
ISB-14
Core Platform
MW: ~20 kDa 1 TME target (MMP-2/9)
  • Single MMP-2/9 cleavage site
  • Proof-of-concept construct
  • Benchmark for all variants
  • Establishes core platform biology
ISB-20
Advanced Targeting
MW: ~20 kDa 3 TME targets (MMPs +)
  • Triple targeting
  • Increased tumor vascular permeability
  • Lead candidate: breast, prostate
  • Increased tumor penetration
ISB-21
Quad-Target Modality
MW: ~40 kDa 4 TME targets (MMPs +)
  • Two cleavage/release sites
  • Binds two CTP molecules
  • Broadest TME coverage
  • Strongest in vivo suppression
ISB-22
Nanobody-Drug Conjugate
MW: ~40 kDa EGFR + 1 TME target (MMPs)
  • Fused to anti-EGFR nanobody
  • Dual targeted action on EGFR-expressing tumors
  • Colorectal, NSCLC, Head & Neck
  • SEC-HPLC confirms EGFR binding
In Vivo Efficacy: Breast Cancer Human xenograft HER2+ model
Buffer Control
Baseline tumor growth
ISB-20 (1 mg/kg)
Low-dose efficacy — moderate response
ISB-14 (5 mg/kg)
Core construct — partial response
ISB-20 (5 mg/kg)
Dose-dependent superior tumor inhibition
ISB-21 (5 mg/kg)
Strongest suppression — quad-target benefit
Trastuzumab (5 mg/kg)
Standard-of-care (SOC) comparator

Key finding: ISB-21 (5 mg/kg) demonstrates the strongest tumor suppression in the HER2+ xenograft model. No body weight loss was observed across TBDS-treated groups.

In Vivo Efficacy: Prostate Cancer Human prostate xenograft model · 5 mg/kg across all treatment arms
Buffer Control
Untreated Baseline
Untreated Baseline
Unrestricted tumor progression. Establishes the growth trajectory against which all treatment arms are compared.
Benchmark for tumor inhibition calculations
ISB-20
5 mg/kg
Strong Response
Significant tumor growth suppression in prostate xenograft. Confirms multi-indication activity of the lead TBDS candidate.
Active across breast AND prostate — platform versatility confirmed
ISB-21
5 mg/kg
Strong Response
Comparable efficacy to ISB-20. Demonstrates that the quad-target, dual-CTP modality extends to prostate adenocarcinoma.
Most potent construct; dual payload increases cytotoxic dose
Docetaxel
5 mg/kg
SOC Comparator
FDA-approved first-line therapy for mCRPC. Provides the most clinically meaningful benchmark for efficacy comparison.
TBDS matches docetaxel efficacy with superior tolerability
Platform Extension: ISB-22 (Nanobody-Drug Conjugate) Expanding TBDS into EGFR-driven oncology via a single recombinant fusion protein

ISB-22: TBDS + Anti-EGFR Nanobody

ISB-22 fuses the PS14 (TBDS core) to a nanobody targeting the EGF receptor — creating a Nanobody-Drug Conjugate (NDC) without traditional conjugation chemistry. A single recombinant protein, one-step design.

Format
Single recombinant fusion protein
MW
~40 kDa · expressed in E. coli · 3-step chromatography purification
Target
EGFR (EGF Receptor) — overexpressed in CRC, NSCLC, HNSCC
Validation
SEC-HPLC confirms ISB-22 effective binding to soluble EGFR

Target Indications

Colorectal Cancer
~150K US cases/yr
EGFR-targeted SOC (cetuximab) limited by RAS mutations. ISB-22 adds physical lysis — avoids molecular resistance
Non-Small Cell Lung
~235K US cases/yr
EGFR mutations in 10–15% of NSCLC. Broad EGFR overexpression in non-mutated tumors creates large addressable population
Head & Neck Cancer
~66K US cases/yr
90%+ of HNSCC cases overexpress EGFR. Resistance to cetuximab is common — TBDS physical mechanism bypasses this
Lead Indications A growing pipeline spanning 5 cancer types across 4 differentiated constructs
Cancer Type ISB-14
TBDS Core		 ISB-20 ISB-21 ISB-22 Key Rationale
Breast Cancer · ✓ ✓ — Strong in vivo inhibition in BC model; ISB-21 competitive with trastuzumab
Prostate Cancer · ✓ ✓ — Comparable to docetaxel in xenograft; key for mCRPC patients
Colorectal Cancer · — — ✓ EGFR-targeted via ISB-22; broad TME targeting
NSCLC (Lung) · — ✓ ✓ EGFR mutations in 10–15%; large addressable market
Head & Neck · — — ✓ 90%+ EGFR overexpression; high unmet need post-cetuximab
✓ Active lead  ·  · Core platform  ·  — Out of scope for this construct

Ready to Partner?

Interspace Biosystems is actively seeking investors, pharma partners, and research collaborators to advance TBDS toward IND-enabling studies and first-in-human trials.

Request Investor Access Pharma Partnership Review the Science